Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Sequencing Methods for Hepatitis C Virus Genotyping Compared

By LabMedica International staff writers
Posted on 04 Sep 2019
Due to its high rate of mutation, hepatitis C virus (HCV) forms viral quasispecies, classified based on the highly variable regions in the envelope protein and nonstructural 5B protein (NS5B). As a result of this large genetic variability, seven genotypes and more than 67 subtypes have been identified.

HCV genotyping is part of the evaluation of newly diagnosed patients and has always been important in guiding treatment. Considering that genotype is a key element in the management of patients infected with HCV, the determination of the genotype is recommended. The technique most frequently used to genotype HCV is quantitative real-time polymerase chain reaction (qRT-PCR). This technique is unable to provide an accurate genotype/subtype for many samples.

Microbiologists and their colleagues working at the Université Catholique de Louvain (Brussels, Belgium) develop an in-house method with the goal of accurately identifying the genotype of all samples. The team analyzed 100 samples from HCV infected patients by the VERSANT HCV Genotype 2.0 LiPA Assay covering frequent HCV types and subtypes. NS5B, 5’UTR and Core homemade sequencing were then performed on these samples. The sequences obtained were compared with the HCV genomic BLAST bank.

The investigators reported that all the samples were characterized by the VERSANT LiPA assay (eight G1a, 17 G1b, six G2, 11 G3, 13 G4, and 10 G6). It was not possible to discriminate between G6 and G1 by the VERSANT LiPA assay for eight samples and 27 had an undetermined genotype. Forty-one samples were sequenced for the three regions: NS5B, 5’UTR and Core. Twenty-three samples were sequenced for two regions: 5′ UTR and Core and 36 samples were sequenced only for NS5B. Of the 100 samples included, 64 samples were analyzed for 5’UTR and Core sequencing and 79 samples were analyzed for NS5B sequencing. The global agreement between VERSANT LiPA assay and sequencing was greater than 95%.

The authors concluded that the high genetic variability of HCV makes it a challenge to correctly determine genotype and subtypes using commercial assays. For undetermined samples, supplementary testing is required. They described new and original methods of sequencing 5’UTR and Core regions to confirm HCV genotypes not discriminated by a commercial assay, in particular by using amplicons already obtained by the VERSANT HCV Genotype 2.0 Line Probe Assay. The study was published on August 22, 2019, in the journal BMC Infectious Diseases.

Related Links:
Université Catholique de Louvain


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Toxoplasma Gondii Immunoassay
Toxo IgM AccuBind ELISA Kit
New
Gold Member
Human Chorionic Gonadotropin Test
hCG Quantitative - R012
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.